^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:naporafenib (ERAS-254) (BRAF inhibitor, pan-RAF inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

    Excerpt:
    ...- Presence of KRAS or BRAF mutation (NSCLC) or NRAS mutation (cutaneous melanoma) in tumor tissue...
    Trial ID:
    NCT02974725
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

    Excerpt:
    ...- Patients with confirmed NRAS-mutated melanoma (cutaneous melanoma only)...
    Trial ID:
    NCT02607813
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Lett
    Title:

    Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells

    Published date:
    09/23/2020
    Excerpt:
    High-throughput kinome screenings further showed that G2/M arrest, particularly following knockdown of polo-like kinase 1 (PLK1), can inhibit the growth of human NRAS-mutant NSCLC cells and those treated with the type II pan-RAF inhibitor LXH254.
    DOI:
    10.1016/j.canlet.2020.09.018